Antibodies to human interleukin-11 receptor
Polynucleotides encoding the human IL-11 receptor and fragments thereof are disclosed. IL-11 receptor proteins, methods for their production, antibodies to human IL-11 receptor, inhibitors of binding of human IL-11 and its receptor and methods for identification of their receptor are also disclosed.
1. An isolated antibody that specifically binds to a human interleukin-11 receptor (IL-11R) protein or a fragment thereof, wherein the human IL-11R protein or fragment thereof consists of an amino acid sequence selected from the group consisting of:
(a) the amino acid sequence of SEQ ID NO:2;
(b) the amino acid sequence of SEQ ID NO:2 from amino acids 24 to 422;
(c) the amino acid sequence of SEQ ID NO:2 from amino acids 24 to 365;
(d) the amino acid sequence of SEQ ID NO:2 from amino acids 391 to 422;
(e) the amino acid sequence of SEQ ID NO:2 from amino acids 112 to 422;
(f) the amino acid sequence of SEQ ID NO:2 from amino acids 112 to 365;
(g) the amino acid sequence of SEQ ID NO:2 from amino acids 24 to 359;
(h) the amino acid sequence of SEQ ID NO:2 from amino acids 24 to 345; and
(i) the amino acid sequence of SEQ ID NO:2 from amino acids 24 to 324.
2. The antibody of claim 1 , wherein said antibody is a neutralizing antibody.
3. The antibody of claim 1 , wherein said antibody blocks binding of IL-11 to a human IL-11 receptor.
4. The antibody of claim 1 , wherein said antibody is a polyclonal antibody.
5. The antibody of claim 1 , wherein said antibody is a monoclonal antibody.
6. A pharmaceutical composition comprising the antibody of claim 1 and a pharmaceutically acceptable carrier.
7. An isolated antibody that specifically binds to a human interleukin-11 receptor (IL-11R) consisting of the amino acid sequence of SEQ ID NO:2 or consisting of the amino acid sequence of SEQ ID NO:2 from amino acids 24 to 422.
8. The isolated antibody of claim 7 , wherein said antibody is a neutralizing antibody.
9. The antibody of claim 7 , wherein said antibody blocks binding of IL-11 to a human IL-11 receptor.
10. The antibody of claim 7 , wherein said antibody is a polyclonal antibody.
11. The antibody of claim 7 , wherein said antibody is a monoclonal antibody.
12. A pharmaceutical composition comprising the antibody of claim 7 and a pharmaceutically acceptable carrier.